TCR2 Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- TCR2 Therapeutics's estimated annual revenue is currently $4.5M per year.
- TCR2 Therapeutics received $125.0M in venture funding in March 2018.
- TCR2 Therapeutics's estimated revenue per employee is $34,313
- TCR2 Therapeutics's total funding is $173.3M.
- TCR2 Therapeutics's current valuation is $153.3M. (January 2022)
Employee Data
- TCR2 Therapeutics has 131 Employees.
- TCR2 Therapeutics grew their employee count by -28% last year.
TCR2 Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Director - Discovery & Innovation Immunology/Pre-Clinical R&D | Reveal Email/Phone |
2 | Director - Manufacturing Sciences and Technologies (MSAT) - External Manufacturing | Reveal Email/Phone |
3 | Clinical Sample Manager | Reveal Email/Phone |
4 | Downstream Vector Process Development Co-op | Reveal Email/Phone |
5 | Sr. Scientist | Reveal Email/Phone |
6 | Senior Research Associate | Reveal Email/Phone |
7 | Group Leader, Translational Sciences | Reveal Email/Phone |
8 | Principal Scientist | Reveal Email/Phone |
9 | MSAT Lead | Reveal Email/Phone |
10 | Senior Accountant | Reveal Email/Phone |
TCR2 Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is TCR2 Therapeutics?
TCR2 is an innovative immunotherapy company developing the next generation of novel T cell receptor therapies for patients suffering from cancer.
keywords:Biotechnology,Healthcare
$173.3M
Total Funding
131
Number of Employees
$4.5M
Revenue (est)
-28%
Employee Growth %
$153.3M
Valuation
N/A
Accelerator
TCR2 Therapeutics News
Zacks: Brokerages Expect TCR2 Therapeutics Inc. (NASDAQ:TCRR) Will Announce Earnings of -$0.74 Per Share. Posted by admin on Apr 20th, 2022.
TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from...
TCR2 Therapeutics, Arbor Biotechnologies Partner on TRuC-T Cell Therapies. Partnership enables TCR2 to evaluate multiple allogeneic candidates...
TCR2 Therapeutics has partnered with Raffit Hassan, MD, at the National Cancer Institute to test TC-210, a mesothelin-specific immunotherapy, ...
TCR² Therapeutics Inc. TCRR has been struggling lately, but the selling pressure may be coming to an end soon. That is because TCRR ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $32.1M | 131 | -17% | $21M |
#2 | $23.6M | 131 | 18% | N/A |
#3 | $20.5M | 132 | 4% | $637M |
#4 | $38.3M | 132 | 18% | N/A |
#5 | $20.5M | 132 | 38% | N/A |
TCR2 Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2016-12-12 | $44.5M | A | MPM Capital | Article |
| 2018-03-22 | $125.0M | B | 6 Dimensions Capital | Article |